Risk of Relapse Among Propensity Score Matched Multiple Sclerosis Patients Receiving Natalizumab or Platform Therapy in the US. Watson C, Bonafede MM, Johnson BH Value Health. 2014 Nov; 17(7):A391. PMID: 27200903. Abstract CommentRecommendBookmarkWatch
